BJU International
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Authors: Grimm P1, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, et all.
Published: 12/02/2012

“Cesium provides everything we want for prostate brachytherapy as both a monotherapy and in combination therapy, including delivery of a high dose of radiation more quickly for high risk patients in a low dose rate ‘setting.’” 

Dr. Bernard W. Taylor, MD

Texas Oncology - Longview Cancer Center